Latest News

Breath Therapeutics cashes in €43,5m


by tg

Inhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova. 

Gilde Healthcare acted as co-investor for Breath Therapeutics’ orphan drug programme. The spin-off company of the Munich-headquartered nebulisation expert PARI Pharma, part of the global Pari Group, said it will use the funds for financing of Phase III trials and US/EU commercialisation.

Breath Therapeutics’ lead programme is a first-in-class therapeutic/med-tech device combination to treat the Bronchiolitis Obliterans Syndrome (BOS), a life-threatening disease that occurs after 65% of lung transplantations. The company managed to administer a liposomal formulation of the immunesuppressant drug cyclosporin A, using an optimised version of PARI Pharma’s eFlow nebulisator, which can monitor therapy compliance, online.

Breath Therapeutics founders and managers have a well-documented track record in immunesuppressant drug development and nebulisation technology: Jens Stegemann (CEO), Anne Burger (CFO), Gerhard Boerner (CSO), Oliver Denk (COO). Graziano Seghezzi, partner at Sofinnova, Karl Nägler, partner at Gimv, and Arthur Franken, partner at Gilde Healthcare will be on the board of directors.

Fungal skin replaces plastics in electronics

In a proof-of-concept study, Doris Danninger and colleagues demonstrate that fungal mycelium skins can be grown and processed to serve as substrates...

Audi and Krajete create CO2 air capture plant

The plant, which binds the greenhouse gas CO2 directly from the air to an inorganic carrier material without pre-drying and stores it in a highly...

Genfit swallows Versantis in €105m deal

The acquisition of Swiss Versantis AG expands Genfit’s pipeline with three programmes: the Phase II-ready candidate VS-01-ACLF designed to treat...

Cultimate Foods UG raises €700.000 in pre-seed financing

Berlin food-tech specialist Cultimate Foods UG has raised €700.000 in a pre-seed round led by Big Idea Ventures LLC, ProVeg International e.V. and...

Belgian researchers create extraembryonic mesoderm cells

The team headed by Dr Vincent Pasque generated human extraembryonic mesoderm cells (EXMCs) that allow in-vitro studies on post-implantation human...

Jolt Capital boosts BC Platforms with $20m

Espoo-based BC Platforms, an international healthcare data provider and software developer, in November has baged an investment of $20m from the...

Resolve Biosciences secures US$71m in funding

The current Series B financing brings Mohnheim-based Resolve Biosciences’ financing up to a total of more than $100m. The finance round followed the...